Innate immune cell counts in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg in CLARITY and CLARITY extension

被引：0
|
作者：
Soelberg-Sorensen, P. [1 ]
Dangond, F. [2 ]
Hicking, C. [3 ]
Giovannoni, G. [4 ]
机构：
[1] Univ Copenhagen, Rigshosp, Dept Neurol, Copenhagen, Denmark
[2] EMD Serono Inc, Billerica, MA USA
[3] Merck KGaA, Darmstadt, Germany
[4] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1141
引用
收藏
页码：598 / 599
页数：2
相关论文
共 50 条
  • [31] Safety and Tolerability of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Final Results from the 120-Week Phase IIIb Extension Trial to the CLARITY Study
    Cook, Stuart
    Comi, Giancarlo
    Rieckmann, Peter
    Rammohan, Kottil
    Soelberg-Soerensenn, Per
    Vermersch, Patrick
    Martin, Emily
    Dangond, Fernando
    Giovannoni, Gavin
    NEUROLOGY, 2016, 86
  • [32] Efficacy of Cladribine Tablets 3.5 mg/ kg in High Disease Activity (HDA) Subgroups of Patients with Relapsing Multiple Sclerosis (RMS) in the CLARITY Study
    Giovannoni, Gavin
    Rammohan, Kottil
    Cook, Stuart
    Comi, Giancarlo
    Rieckmann, Peter
    Soelberg-Sorensen, Per
    Vermersch, Patrick
    Dangond, Fernando
    Hicking, Christine
    King, John
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (03) : 396 - 397
  • [33] Efficacy of cladribine tablets 3.5 mg/kg in high disease activity (HDA) subgroups of patients with relapsing multiple sclerosis (RMS) in the CLARITY study
    Giovannoni, Gavin
    Rammohan, Kottil
    Cook, Stuart
    Comi, Giancarlo
    Rieckmann, Peter
    Soelberg-Sorensen, Per
    Vermersch, Patrick
    Dangond, Fernando
    Hicking, Christine
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (02) : NP6 - NP6
  • [34] Efficacy of Cladribine Tablets 3.5 mg/kg in High Disease Activity (HDA) Subgroups of Patients with Relapsing Multiple Sclerosis (RMS) in the CLARITY Study
    Giovannoni, Gavin
    Rammohan, Kottil
    Cook, Stuart
    Comi, Giancarlo
    Rieckmann, Peter
    Soelberg-Sorensen, Per
    Vermersch, Patrick
    Dangond, Fernando
    Hicking, Christine
    NEUROLOGY, 2017, 88
  • [35] Clinical efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis (RRMS): final results from the 120-week Phase IIIb extension trial to the CLARITY study
    Giovannoni, G.
    Comi, G.
    Cook, S.
    Rieckmann, P.
    Rammohan, K.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Martin, E.
    Dangond, F.
    SWISS MEDICAL WEEKLY, 2016, 146 : 79S - 79S
  • [36] Safety and tolerability of cladribine tablets in patients with relapsing-remitting multiple sclerosis (RRMS): final results from the 120-week Phase IIIb extension trial to the CLARITY study
    Cook, S.
    Comi, G.
    Rieckmann, P.
    Rammohan, K.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Martin, E.
    Dangond, F.
    Giovannoni, G.
    SWISS MEDICAL WEEKLY, 2016, 146 : 78S - 78S
  • [37] ADJUSTING FOR TREATMENT SWITCHING IN THE RELAPSING-REMITTING MULTIPLE SCLEROSIS CLARITY TRIAL AND THE CLARITY EXTENSION STUDY
    Gorrod, Bell H.
    Latimer, N.
    Damian, D.
    Hettle, R.
    Harty, G. T.
    Wong, S. L.
    VALUE IN HEALTH, 2017, 20 (09) : A718 - A718
  • [38] Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies
    Gavin Giovannoni
    Giancarlo Comi
    Kottil Rammohan
    Peter Rieckmann
    Fernando Dangond
    Birgit Keller
    Dominic Jack
    Patrick Vermersch
    Advances in Therapy, 2021, 38 : 4975 - 4985
  • [39] Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies
    Giovannoni, Gavin
    Comi, Giancarlo
    Rammohan, Kottil
    Rieckmann, Peter
    Dangond, Fernando
    Keller, Birgit
    Jack, Dominic
    Vermersch, Patrick
    ADVANCES IN THERAPY, 2021, 38 (09) : 4975 - 4985
  • [40] Oral cladribine in relapsing-remitting multiple sclerosis: study design of the 2-year, Phase IIIb CLARITY (CLAdRIbine tablets Treating multiple sclerosis orallY) extension study
    Giovannoni, G.
    Cook, S.
    Greenberg, S.
    Chang, P.
    Comi, G.
    Rieckmann, P.
    Sorensen, P. Soelberg
    Vermersch, P.
    JOURNAL OF NEUROLOGY, 2008, 255 : 206 - 206
12345